(Last updated : 2024-09-12 08:45:21)
  Masao Nakata
   Department   Kawasaki Medical School  Kawasaki Medical School, Department of General Thoracic Surgery,
   Position   Professor
■ Present specialized field
Respiratory surgery 
■ BooK
1. 2004   Evaluation of ischmic limbs by measuring transcutaneous oxygen tension and skin perfusion pressure, Breakthrough in the Treatment for Critical Limb Ischemia in Japan 
■ Journal
1. 2024/07/30 Predictive Value of PERCIST for Locally Advanced Non-Small Cell Lung Cancer Treated with Preoperative Induction Therapy – A Multicenter Study in Japan  Link
2. 2024/06/28 Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer  Link
3. 2023/11/10 A case of an atypical variant of type A thymoma presenting with a gradually enlarging tumor over a 10-year period 
4. 2023/11/01 INFORMED CONSENT IN SURGERY FOR PRIMARY LUNG CANCER 
5. 2023/05/19 Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201  Link
Display all(90)
■ Presentation
1. 2024/09/07 Aging alteration of biomarkers and its prognostic role in elderly lung cancer patients treated with adjuvant S-1 chemotherapy -a subsidiary study of Setouchi Lung Cancer Group study 1201(SLCG1201)- (Poster notice,General) 
2. 2024/09/07 Perioperative Durvalumab for Resectable NSCLC
Updated Outcomes from the Phase 3 AEGEAN Trial (Speech,General) 
3. 2024/05/15 Serum NY-ESO-1 and XAGE1 antibodies are potentially predictive and immunomonitoring markers of response to immune checkpoint therapy in non-small cell lung cancer (Speech,General) 
4. 2022/08/06 Serum NY-ESO-1 and XAGE1 antibodies predict and monitor clinical responses to immune checkpoint therapy for NSCLC (Poster notice,General) 
5. 2022/04/15 Conversion or salvage surgery for patients with unresectable stage III non-small-cell lung cancer (Speech,Panelist at Symposium/Workshop (Applied)) 
Display all(51)